Article

Higher Uric Acid Linked With Stronger Postmenopausal Bones

Women with higher uric acid levels around and after menopause show less bone loss. What could this mean?

Higher levels of serum uric acid (UA) might counteract osteoporosis in peri- and postmenopausal women by providing higher bone mineral density (BMD) and lower bone turnover, which would presumably imply reduced fracture risk.

This intriguing result comes from a study of 356 peri- and postmenopausal women with a mean age of 60.5 in Australia. The research team took DXA measurements at baseline and at each followup visit and averaged them over a decade, At the final visit in the study period, they also measured calciotropic hormones and bone turnover markers.

Even taking lean body mass and fat mass into account, at the end of the study all women who had higher UA levels also maintained good lumbar spine, forearm, and overall body BMD levels. (UA didn't seem to benefit pelvic bone mass, however.)

It would be premature to regard UA as an osteoporosis preventive, observed study team member Markus Seibel MD, who is director of the ANZAC Research Institute’s Bone Research Program.The underlying mechanisms aren't yet elaborated, he pointed out; nor is there enough information yet to judge the balance between any osteoporosis benefit and the adverse effects of high UA such as gout.

Related Videos
Kimberly A. Davidow, MD: Elucidating Risk of Autoimmune Disease in Childhood Cancer Survivors
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
© 2025 MJH Life Sciences

All rights reserved.